Thermo Fisher Scientifics Advanced Granulation Technology Media Manufacturing Site Expands in Scotland
Essential products needed for the production of biotherapeutics and vaccines for diseases such as influenza and dengue fever will be produced in Scotland, following the launch of the new state-of-the-art facility near Glasgow.
Thermo Fisher Scientific has expanded its campus in Inchinnan, Scotland, with the addition of a cutting-edge facility that will manufacture a novel and proprietary dry media powder known as Gibco Advanced Granulation Technology (AGT). AGT products are animal-origin free, single-component, particulate-free powders for chemically defined cell culture. The AGT dry media format reduces the number of components necessary in cell culture manufacturing processes. Used to manufacture biologics, including vaccines, anti-cancer therapeutics and other life-saving drugs, AGT offers customers the benefits of traditional liquid media without the associated cost, storage, and transportation challenges.
The £14 million investment increases the assurance of supply for customers and complements another Thermo Fisher facility in Grand Island, New York, where AGT is also manufactured. The new facility will add to the Inchinnan site’s existing manufacturing operations, which produce liquid media for a range of research and production applications.
“This is a strategically important facility that will secure supplies for our target markets all over the world,” said Mark Smedley, President of Europe, Middle East and Africa, Life Sciences Solutions, for Thermo Fisher. “It’s important to choose the right location for a factory of this significance, and we felt the depth of experience, skills and expertise at Inchinnan made it the perfect place to make this investment.”
This investment is linked to on-going support from Scottish Enterprise to assist Thermo Fisher in expanding the company’s global manufacturing network.
"Congratulations to Thermo Fisher on the opening of their impressive new facility at Inchinnan,” said Paul Lewis, Managing Director, Scottish Development International and Scottish Enterprise International Operations. "Scotland is already home to a thriving life sciences cluster which is recognised worldwide as one of the most accessible, well-connected and collaborative in Europe. It is major investments like this that allow us to continue to attract ambitious, international companies such as Thermo Fisher to not only locate in Scotland but to strengthen their business base here and to invest in long-term growth."
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.